LARTRUVO (olaratumab)

Billing Information Ordering Information
HCPCS Codes
Code Description Setting
C9485 Injection, olaratumab, 10 mg Hospital outpatient
J9999 Not otherwise classified, antineoplastic drugs Physician office
J3490 Unclassified drugs Physician office
J3590 Unclassified biologics Physician office
NDC
Code Dosage form and strength
00002-8926-01 Lartruvo (olaratumab for injection) 500 mg/50 mL (10 mg/mL) solution, single-dose vial
00002-7190-01 Lartruvo (olaratumab for injection) 190 mg/19 mL (10 mg/mL) solution, single-dose vial
Diagnosis Codes
Only the Non-GIST soft tissue sarcoma code
ICD-10 Code Description
C47.0 Malignant neoplasm of peripheral nerves of head, face, and neck
C47.1 Malignant neoplasm of peripheral nerves of upper limb, including shoulder
C47.10 Malignant neoplasm of peripheral nerves of unspecified upper limb, including shoulder
C47.11 Malignant neoplasm of peripheral nerves of right upper limb, including shoulder
C47.12 Malignant neoplasm of peripheral nerves of left upper limb, including shoulder
C47.2 Malignant neoplasm of peripheral nerves of lower limb, including hip
C47.20 Malignant neoplasm of peripheral nerves of unspecified lower limb, including hip
C47.21 Malignant neoplasm of peripheral nerves of right lower limb, including hip
C47.22 Malignant neoplasm of peripheral nerves of left lower limb, including hip
C47.3 Malignant neoplasm of peripheral nerves of thorax
C47.4 Malignant neoplasm of peripheral nerves of abdomen
C47.5 Malignant neoplasm of peripheral nerves of pelvis
C47.6 Malignant neoplasm of peripheral nerves of trunk, unspecified
C47.8 Malignant neoplasm of overlapping sites of peripheral nerves and autonomic nervous system
C47.9 Malignant neoplasm of peripheral nerves and autonomic nervous system, unspecified
C48.0 Malignant neoplasm of retroperitoneum and peritoneum
C48.1 Malignant neoplasm of specified parts of peritoneum
C48.2 Malignant neoplasm of peritoneum, unspecified
C48.8 Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum
C49 Malignant neoplasm of other connective and soft tissue
C49.1 Malignant neoplasm of connective and soft tissue of upper limb, including shoulder
C49.10 Malignant neoplasm of connective and soft tissue of unspecified upper limb, including shoulder
C49.11 Malignant neoplasm of connective and soft tissue of right upper limb, including shoulder
C49.12 Malignant neoplasm of connective and soft tissue of left upper limb, including shoulder
C49.2 Malignant neoplasm of connective and soft tissue of lower limb, including hip
C49.20 Malignant neoplasm of connective and soft tissue of unspecified lower limb, including hip
C49.21 Malignant neoplasm of connective and soft tissue of right lower limb, including hip
C49.22 Malignant neoplasm of connective and soft tissue of left lower limb, including hip
C49.3 Malignant neoplasm of connective and soft tissue of thorax
C49.4 Malignant neoplasm of connective and soft tissue of abdomen
C49.5 Malignant neoplasm of connective and soft tissue of pelvis
C49.6 Malignant neoplasm of connective and soft tissue of trunk, unspecified
C49.8 Malignant neoplasm of overlapping sites of connective and soft tissue
C49.9 Malignant neoplasm of connective and soft tissue, unspecified
C53.0 Malignant neoplasm of endocervix
C54.0 Malignant neoplasm of isthmus uteri
C54.1 Malignant neoplasm of endometrium
C54.2 Malignant neoplasm of myometrium
C54.3 Malignant neoplasm of fundus uteri
C54.8 Malignant neoplasm of overlapping sites of corpus uteri
C54.9 Malignant neoplasm of corpus uteri, unspecified
C55 Malignant neoplasm of uterus, part unspecified
C78.00 Secondary malignant neoplasm of unspecified lung
C78.01 Secondary malignant neoplasm of right lung
C78.02 Secondary malignant neoplasm of left lung
Z80.49 Family history of malignant neoplasm of other genital organs
Drug Administration CPT® Code
Code Description
96413 Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug

Lilly has contracted with a network of specialty distributors and one specialty pharmacy to provide customers access to LARTRUVO.

If purchasing LARTRUVO directly, you may use one of the five specialty distributors listed here. You also have the option of ordering from our authorized specialty pharmacy partner shown below. For more information on purchasing, dispensing, or returning Lilly products, visit LillyTrade.com. For inquiries about this matter, contact Lilly at 1-800-LillyRx (1-800-545-5979).

Specialty Distributor Network
AmerisourceBergen Specialty Group
Order Entry Code: 190 mg/19 mL and 500 mg/50 mL (10 mg/mL), single-dose vials - 45884
Oncology Supply ASD Healthcare
P: (800) 633-7555, F: (800) 248-8205
oncologysupply.com
P: (800) 746-6273, F: (800) 547-9413
asdhealthcare.com
Cardinal Health Specialty Pharmaceutical Distribution
Order Entry Code: 190 mg/19 mL and 500 mg/50 mL (10 mg/mL), single-dose vials - 5203856
Oncology Clinics Hospitals
P: (877) 453-3972, F: (888) 345-4916
cardinalhealth.com
/specialtyonline
P: (866) 677-4844, F: (888) 345-4916
cardinalhealth.com
/specialtyonline
CuraScript Specialty Distribution
Order Entry Code: 190 mg/19 mL and 500 mg/50 mL (10 mg/mL), single-dose vials - 268348
P: (877) 599-7748, F: (800) 862-6208, curascriptsd.com
McKesson Specialty Care Distribution Corporation
Order Entry Code: 190 mg/19 mL and 500 mg/50 mL (10 mg/mL), single-dose vials - 5005803
McKesson Specialty Health McKesson Plasma and Biologics
P: (800) 482-6700, F: (800) 289-9285
mscs.mckesson.com
P: (877) 625-2566, F: (888) 752-7626
connect.mckesson.com
Smith Medical Partners
Order Entry Code: 190 mg/19 mL and 500 mg/50 mL (10 mg/mL), single-dose vials - 5525472
P: (800) 292-9653, F: (630) 227-9220, smpspecialty.com
Authorized Specialty Pharmacy
Accredo
P: (877) 732-3431, F: (800) 391-9707, accredo.com

Prescribing Information

This information is presented for informational purposes only and is not intended to provide reimbursement or legal advice. Laws, regulations, and policies concerning reimbursement are complex and are updated frequently. Individual coding decisions should be based upon diagnosis and treatment of individual patients. Eli Lilly and Company does not guarantee success in obtaining insurance payments. While we have made an effort to be current as of the issue date of this website, the information may not be as current or comprehensive when you view it. Providers should contact third-party payers for specific information on their coverage, coding, and payment policies. Please consult with your legal counsel or reimbursement specialist for any reimbursement or billing questions. For more information please call the Lilly PatientOne program at 1-866-472-8663.

† FDA standard NDC has been “zero-filled” to ensure creation of an 11-digit code that meets HIPAA standards. The zero-fill location is indicated in bold.